These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 97712)
41. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug. Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413 [TBL] [Abstract][Full Text] [Related]
42. Neuropsychopharmacological profile of remoxipride in comparison with clozapine. Skuza G; Rogóz Z; Wieczorek A Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546 [TBL] [Abstract][Full Text] [Related]
43. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Ellenbroek BA; Peeters BW; Honig WM; Cools AR Psychopharmacology (Berl); 1987; 93(3):343-8. PubMed ID: 2893411 [TBL] [Abstract][Full Text] [Related]
44. Antagonism of AP-5- and amphetamine-induced behaviour by timelotem as compared with clozapine and haloperidol. Schmidt WJ; Krähling H; Ruhland M Life Sci; 1987 Oct; 41(16):1909-14. PubMed ID: 2889124 [TBL] [Abstract][Full Text] [Related]
45. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Costall B; Naylor RJ Eur J Pharmacol; 1976 Nov; 40(1):9-19. PubMed ID: 791660 [TBL] [Abstract][Full Text] [Related]
46. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series. Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM; Wauquier A Arzneimittelforschung; 1975 Aug; 25(8):1287-94. PubMed ID: 1242360 [TBL] [Abstract][Full Text] [Related]
47. Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats. Wambebe C Jpn J Pharmacol; 1987 Feb; 43(2):121-8. PubMed ID: 2883335 [TBL] [Abstract][Full Text] [Related]
48. Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm. Carvey PM; Nath ST; Kao LC; Zhang TJ; Lin DH; Singh R; Amdur RL; Klawans HL Eur J Pharmacol; 1990 Aug; 184(1):43-53. PubMed ID: 2209714 [TBL] [Abstract][Full Text] [Related]
49. Comparison of the effects of clozapine, haloperidol, chlorpromazine and d-amphetamine on performance on a time-constrained progressive ratio schedule and on locomotor behaviour in the rat. Mobini S; Chiang TJ; Ho MY; Bradshaw CM; Szabadi E Psychopharmacology (Berl); 2000 Sep; 152(1):47-54. PubMed ID: 11041315 [TBL] [Abstract][Full Text] [Related]
50. The prediction of sedative potency of neuroleptics. Loew DM Mod Probl Pharmacopsychiatry; 1970; 5():47-50. PubMed ID: 5527167 [No Abstract] [Full Text] [Related]
51. [Behavioral effects of quinupramine, a new tricyclic antidepressant]. Ueki S; Yamamoto T; Shimazoe T; Shibata S; Tani Y; Machida K; Hojo M; Yoshida Y; Tatsumi H Nihon Yakurigaku Zasshi; 1988 Jun; 91(6):359-69. PubMed ID: 3417209 [TBL] [Abstract][Full Text] [Related]
52. Effects of prostaglandin E1, E2 and 16,16-dimethyl-E2 on gastric mucosal microcirculation and basal acid output in the rat. Holm-Rutili L Acta Physiol Scand; 1986 Jul; 127(3):313-21. PubMed ID: 3463127 [TBL] [Abstract][Full Text] [Related]
53. Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol. Rebec GV; Peirson EE; McPherson FA; Brugge K Psychopharmacology (Berl); 1982; 77(4):360-6. PubMed ID: 6813898 [TBL] [Abstract][Full Text] [Related]
54. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. Tang AH; Franklin SR; Himes CS; Smith MW; Tenbrink RE J Pharmacol Exp Ther; 1997 Apr; 281(1):440-7. PubMed ID: 9103528 [TBL] [Abstract][Full Text] [Related]
55. Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha. Förstermann U; Heldt R; Hertting G Psychopharmacology (Berl); 1983; 80(4):365-70. PubMed ID: 6414007 [TBL] [Abstract][Full Text] [Related]
56. Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat. Halperin R; Guerin JJ; Davis KL Life Sci; 1983 Aug; 33(6):585-92. PubMed ID: 6684202 [TBL] [Abstract][Full Text] [Related]
57. Behavioural correlates to the dopamine D-1 and D-2 antagonists. Christensen AV; Arnt J; Hyttel J; Svendsen O Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830 [TBL] [Abstract][Full Text] [Related]
58. Effect of muscarinic receptor agonists on animal models of psychosis. Karan RS; Ravishankar P; Pandhi P Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):169-72. PubMed ID: 10893700 [TBL] [Abstract][Full Text] [Related]
59. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects. Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833 [No Abstract] [Full Text] [Related]